NCT02487979: A trial that was reported late by National Cancer Institute (NCI)
This trial has reported, although it was 34 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02487979 |
|---|---|
| Title | A Phase 2 Study of GPNMB-Targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; NSC# 763737), in Recurrent or Refractory Osteosarcoma |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Feb. 16, 2016 |
| Completion date | June 30, 2017 |
| Required reporting date | June 30, 2018, midnight |
| Actual reporting date | Aug. 3, 2018 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 34 |